Current:Home > InvestX, formerly Twitter, tests charging new users $1 a year to use basic features -消息
X, formerly Twitter, tests charging new users $1 a year to use basic features
View
Date:2025-04-15 23:51:07
X, the social media platform formerly known as Twitter, announced Tuesday it is testing out a subscription model in which it will charge new users $1 a year to use basic features.
The social media giant said it was launching its "Not a Bot" annual subscription method in New Zealand and the Philippines as a test run. Existing users will not be impacted during the test.
"This will evaluate a potentially powerful measure to help us combat bots and spammers on X, while balancing platform accessibility with the small fee amount," X said, adding that the charge won't be a "profit driver."
Users who create new accounts will verify their account with their phone number and then pay $1 USD. They will then be able to use key features like posting, liking, replying to, reposting, bookmarking and quoting posts. New users who opt out of the subscription will be relegated to "read only" functions, such as reading posts, watching videos and following accounts, according to X.
The announcement aligns with previous remarks from X owner Elon Musk, who took over the platform in 2022. Last month, Musk said he was considering charging a "small monthly payment" to use X during a live-streamed conversation with Israeli Prime Minister Benjamin Netanyahu, saying at the time the fee would be meant to keep bots off the platform. At the same event, Musk said X has 550 million monthly users that generate 100 million to 200 million posts a day.
Earlier this year, Musk also imposed temporary daily limits on posts users can view to, he said, "address extreme levels of data scraping & system manipulation."
Currently, X has a premium subscription service, charging users for certain features, including being able to edit a post and having prioritized rankings in conversations and search. Pricing for the service starts at $8 a month.
- In:
- Elon Musk
Christopher Brito is a social media manager and trending content writer for CBS News.
veryGood! (2356)
Related
- Travis Hunter, the 2
- 27 Ways Hot Weather Can Kill You — A Dire Warning for a Warming Planet
- You'll Flip a Table Over These Real Housewives of New Jersey Season 13 Reunion Looks
- Kid Cudi says he had a stroke at 32. Hailey Bieber was 25. How common are they?
- Don't let hackers fool you with a 'scam
- Moderna sues Pfizer over COVID-19 vaccine patents
- Long COVID and the labor market
- Young adults are using marijuana and hallucinogens at the highest rates on record
- Apple iOS 18.2: What to know about top features, including Genmoji, AI updates
- Gwyneth Paltrow Shares Sex Confessions About Her Exes Brad Pitt and Ben Affleck
Ranking
- 'Squid Game' without subtitles? Duolingo, Netflix encourage fans to learn Korean
- Priyanka Chopra Recalls Experiencing “Deep” Depression After Botched Nose Surgery
- You'll Flip a Table Over These Real Housewives of New Jersey Season 13 Reunion Looks
- Trump Nominee to Lead Climate Agency Supported Privatizing U.S. Weather Data
- Juan Soto to be introduced by Mets at Citi Field after striking record $765 million, 15
- Are Antarctica’s Ice Sheets Near a Climate Tipping Point?
- Whatever happened to the new no-patent COVID vaccine touted as a global game changer?
- How the Love & Death Costumes Hide the Deep, Dark Secret of the True Crime Story
Recommendation
'Kraven the Hunter' spoilers! Let's dig into that twisty ending, supervillain reveal
Kim Kardashian’s SKIMS Has Mother’s Day Gifts Mom Will Love: Here Are 13 Shopping Editor-Approved Picks
Alberta’s New Climate Plan: What You Need to Know
New Hampshire Utility’s Move to Control Green Energy Dollars is Rebuffed
Will the 'Yellowstone' finale be the last episode? What we know about Season 6, spinoffs
Gwyneth Paltrow’s Daughter Apple Martin Pokes Fun at Her Mom in Rare Footage
Released during COVID, some people are sent back to prison with little or no warning
FDA authorizes first revamp of COVID vaccines to target omicron